인간 항균제 감수성 검사 시장 예측(2026-2032년)

The Human Antimicrobial Susceptibility Testing Market is projected to grow by USD 6.50 billion at a CAGR of 6.55% by 2032.

Human antimicrobial susceptibility testing (AST) is a core clinical microbiology function used to determine whether bacteria, fungi, or other pathogens are susceptible, intermediate, or resistant to antimicrobial agents. As antimicrobial resistance (AMR) continues to threaten patient safety, surgical outcomes, cancer care, transplant medicine, intensive care, and infection control programs, demand is increasing for faster, standardized, and clinically actionable AST workflows. The World Health Organization recognizes AMR as one of the top global public health threats, and global health evidence links bacterial AMR to substantial mortality, longer hospital stays, and higher treatment complexity. The executive priority is no longer limited to identifying an organism; healthcare systems increasingly need resistance mechanism detection, minimum inhibitory concentration interpretation, stewardship-ready reporting, and connectivity to surveillance platforms. Human AST supports targeted therapy, reduces inappropriate broad-spectrum antimicrobial use, and strengthens public health monitoring by linking laboratory results with epidemiology, pharmacy data, and clinical outcomes. Adoption is being shaped by clinical guidelines, laboratory accreditation requirements, bloodstream infection protocols, sepsis management pathways, and national AMR action plans. Key technology areas include disk diffusion, broth microdilution, automated phenotypic systems, gradient diffusion, molecular resistance testing, rapid AST platforms, mass spectrometry-enabled workflows, and digital interpretation tools. The most resilient strategies combine reliable phenotypic confirmation with faster diagnostics and antimicrobial stewardship integration, enabling clinicians to move from empiric therapy toward evidence-based treatment decisions.

Transformative Shifts in the Human AST Landscape

The human antimicrobial susceptibility testing landscape is undergoing a structural shift from isolated laboratory testing toward integrated, time-sensitive clinical decision support. Traditional culture-based AST remains essential because it measures organism behavior in the presence of antimicrobial agents, but hospitals are increasingly prioritizing shorter turnaround times for high-risk infections such as sepsis, pneumonia, urinary tract infections, and healthcare-associated infections. This shift is supported by automation, rapid phenotypic testing, molecular resistance marker identification, and direct-from-positive-blood-culture workflows. Clinical laboratories are also moving from manual result review toward standardized interpretive criteria aligned with recognized breakpoints, quality control protocols, and stewardship reporting needs. Another important transformation is the expansion of AST beyond acute hospital laboratories into reference laboratories, outpatient networks, and regional surveillance systems. Growing emphasis on antimicrobial stewardship has made AST data a strategic asset for formulary decisions, local antibiogram development, infection prevention, and empiric therapy guideline updates. At the same time, laboratories face operational constraints, including trained workforce shortages, reagent standardization challenges, evolving breakpoint updates, specimen transport limitations, and the need to validate new methods against reference standards. These pressures are encouraging investment in interoperable platforms, laboratory information system integration, and diagnostics that deliver both speed and confidence without compromising clinical reliability.

Cumulative Impact of Artificial Intelligence on Human AST

Artificial intelligence is beginning to influence human antimicrobial susceptibility testing by improving image analysis, pattern recognition, workflow prioritization, quality control review, and predictive interpretation. In microbiology laboratories, AI-enabled tools can support colony recognition, zone diameter reading, digital plate interpretation, anomaly detection, and automated flagging of unusual resistance phenotypes. In clinical settings, AI can help combine AST results with patient history, renal function, infection site, prior antibiotic exposure, local resistance patterns, and stewardship rules to support more precise therapy recommendations. The cumulative impact is greatest when AI is implemented as an assistive layer that enhances standardization, reduces repetitive manual interpretation, and accelerates clinician notification, while maintaining expert oversight and validated laboratory procedures. AI also has public health relevance because aggregated AST data can be analyzed to identify emerging resistance clusters, detect changes in resistance trends, and support hospital-level or regional AMR surveillance. However, responsible adoption requires transparent validation, bias assessment across diverse pathogen populations, cybersecurity controls, explainable outputs, human factors testing, and alignment with regulatory and clinical governance requirements. AI should not replace confirmatory susceptibility testing where phenotypic evidence is clinically required; rather, it can improve throughput, consistency, and the timeliness of actionable antimicrobial resistance insights.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, the Middle East, and Africa

Asia-Pacific is characterized by high infectious disease burden, dense urban populations, expanding hospital networks, and significant AMR surveillance priorities, making human antimicrobial susceptibility testing central to clinical care and public health. Countries across the region are strengthening laboratory capacity, promoting stewardship programs, and expanding access to automated and rapid diagnostic workflows, although adoption varies widely between advanced healthcare systems and resource-constrained settings. North America demonstrates strong uptake of standardized AST, sepsis protocols, automated microbiology systems, electronic medical record integration, and antimicrobial stewardship programs, with hospitals and reference laboratories emphasizing rapid reporting and surveillance-quality data. Latin America is advancing AMR monitoring through national reference networks and hospital infection-control initiatives, but laboratory infrastructure differences, access constraints, and workforce needs continue to influence AST standardization. Europe benefits from mature regulatory oversight, harmonized breakpoint interpretation, cross-border AMR monitoring, and strong stewardship frameworks, supporting consistent AST quality across many healthcare systems. The Middle East is increasingly prioritizing AST as part of hospital modernization, infection prevention, antimicrobial stewardship, and digital health programs, particularly in tertiary care and medical tourism hubs, while regional variation remains linked to laboratory resources and policy implementation. Africa faces some of the most urgent needs for expanded AST access due to infectious disease burden and rising resistance, with progress focused on strengthening diagnostic infrastructure, quality assurance, workforce training, specimen referral systems, and surveillance connectivity to support evidence-based antimicrobial use.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries are increasingly aligning human antimicrobial susceptibility testing with national AMR action plans, hospital stewardship initiatives, and regional laboratory-strengthening programs, with priorities centered on capacity building, quality assurance, and affordable access to reliable diagnostics. The GCC is investing in advanced hospital infrastructure, infection prevention, antimicrobial stewardship, and digital health systems, creating favorable conditions for automated AST and rapid diagnostic adoption in tertiary care environments. The European Union provides one of the most coordinated environments for AST standardization, supported by harmonized surveillance systems, evidence-based breakpoint guidance, and policy emphasis on responsible antimicrobial use across human health. BRICS countries represent a diverse AST environment, combining major infectious disease burdens, large hospital networks, growing diagnostic manufacturing capacity, and active AMR policy development, while still facing uneven access and laboratory quality variation across regions. G7 countries generally demonstrate mature clinical microbiology capacity, high stewardship penetration, and strong public health surveillance, making AST data increasingly important for antimicrobial policy, hospital benchmarking, and research into resistance mechanisms. NATO member countries have a strategic interest in AST because AMR affects military medicine, trauma care, field hospitals, biodefense readiness, and multinational healthcare interoperability; this reinforces the need for standardized testing, rapid pathogen response, secure data exchange, and resilient laboratory networks across civilian and defense health systems.

Key Country Insights in Human Antimicrobial Susceptibility Testing

The United States has a highly developed human AST ecosystem supported by clinical laboratory standards, antimicrobial stewardship requirements, hospital quality programs, and advanced infectious disease diagnostics, with strong focus on rapid bloodstream infection testing and AMR surveillance. Canada emphasizes standardized laboratory practices, stewardship integration, and national resistance monitoring, with provincial healthcare structures shaping implementation. Mexico is strengthening AST capacity through public health surveillance and hospital laboratory modernization, while access variability remains important across regions. Brazil has substantial AST demand due to large hospital networks, infectious disease complexity, and AMR monitoring needs, with reference laboratories playing an important role in standardization. The United Kingdom maintains strong AST governance through national laboratory guidance, stewardship policies, and surveillance programs, supporting evidence-based prescribing across healthcare settings. Germany combines advanced laboratory infrastructure, hospital infection-control programs, and robust diagnostic adoption, while France emphasizes stewardship, surveillance, and standardized susceptibility reporting. Russia has significant need for AST across hospital and public health settings, with growing attention to resistant healthcare-associated pathogens. Italy and Spain continue to rely on AST to address hospital-acquired infections, carbapenem-resistant organisms, and stewardship-driven prescribing improvements. China is expanding AST capacity through hospital modernization, surveillance networks, and investment in rapid diagnostics, driven by large patient volumes and AMR containment priorities. India has urgent AST needs due to high infectious disease burden, diverse healthcare access, and major antimicrobial stewardship challenges, making affordable, reliable, and scalable testing critical. Japan has advanced clinical microbiology systems, strict quality expectations, and strong use of AST in hospital infection management. Australia benefits from structured surveillance, stewardship programs, and strong laboratory quality systems, while South Korea emphasizes rapid diagnostics, hospital infection control, and monitoring of resistant organisms in high-acuity settings.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize AST solutions that improve clinical turnaround time while preserving validated phenotypic accuracy and alignment with recognized interpretive standards. Product and laboratory strategies should focus on direct-from-sample or direct-from-positive-culture workflows for critical infections, automated quality control, seamless laboratory information system integration, and stewardship-ready reporting that translates susceptibility results into practical prescribing support. Decision-makers should invest in workforce training, breakpoint update management, method verification, external quality assessment participation, and data governance to ensure AST results remain clinically reliable and comparable across sites. Partnerships with hospitals, public health networks, and reference laboratories can strengthen AMR surveillance and support local antibiogram development. Organizations should also design solutions for varied infrastructure levels, including high-throughput automated systems for tertiary hospitals and cost-effective standardized methods for resource-limited settings. AI-enabled features should be deployed with transparent validation, explainable outputs, cybersecurity safeguards, and human expert review. Finally, industry leaders should align product development with antimicrobial stewardship, infection prevention, and public health reporting needs, because the value of AST is increasingly measured by its contribution to faster targeted therapy, reduced inappropriate antimicrobial use, and improved resistance monitoring.

Research Methodology

This executive summary is developed through a structured secondary research methodology focused on verified, data-backed evidence from clinical microbiology standards, peer-reviewed literature, public health agencies, AMR surveillance programs, hospital stewardship guidance, regulatory publications, and laboratory quality frameworks. The analysis emphasizes clinically relevant drivers, technology adoption patterns, regional policy priorities, and operational barriers affecting human antimicrobial susceptibility testing. Sources considered include internationally recognized guidance on susceptibility testing methods and breakpoint interpretation, national AMR action plans, infectious disease surveillance publications, healthcare quality requirements, and scientific studies evaluating AST workflow performance. Insights were synthesized using triangulation across clinical, regulatory, public health, and laboratory operations perspectives to avoid reliance on a single data source. The methodology excludes market sizing, market share estimation, revenue forecasting, and vendor comparison. Instead, it focuses on evidence-based interpretation of adoption trends, workflow transformation, artificial intelligence implications, regional readiness, and strategic priorities for stakeholders involved in human AST across hospitals, reference laboratories, public health systems, and stewardship programs.

Conclusion

Human antimicrobial susceptibility testing is becoming increasingly strategic as healthcare systems confront antimicrobial resistance, sepsis risk, healthcare-associated infections, and the need for more precise antimicrobial therapy. The field is moving toward faster, more automated, digitally connected, and stewardship-oriented workflows, but the foundation remains rigorous laboratory quality, validated testing methods, and standardized interpretation. Regional and country-level adoption differs according to healthcare infrastructure, surveillance maturity, workforce availability, and policy execution, yet the global direction is consistent: AST data must become faster, more interoperable, and more actionable. Artificial intelligence can enhance efficiency and surveillance intelligence, but its value depends on responsible validation and expert oversight. For industry leaders, the strongest opportunities lie in solutions that connect reliable susceptibility testing with clinical decision support, public health reporting, and scalable implementation models. As AMR continues to challenge modern medicine, human AST will remain a critical pillar of patient care, infection prevention, antimicrobial stewardship, and global health security.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Human Antimicrobial Susceptibility Testing Market, by Product Type

• 7.1. Introduction
• 7.2. Instruments
  • 7.2.1. Automated AST Systems
  • 7.2.2. Semi-Automated AST Systems
  • 7.2.3. Manual AST Instruments
  • 7.2.4. Microbiology Analyzers
• 7.3. Consumables
  • 7.3.1. AST Panels & Cards
  • 7.3.2. Culture Media
  • 7.3.3. Reagents & Assay Kits
  • 7.3.4. Antibiotic Discs
• 7.4. Software
  • 7.4.1. Laboratory Information System (LIS) Integration Tools
  • 7.4.2. AI-Based Resistance Interpretation Software
• 7.5. Services
  • 7.5.1. Maintenance & Calibration Services
  • 7.5.2. Training & Consulting Services

8. Human Antimicrobial Susceptibility Testing Market, by Technology

• 8.1. Introduction
• 8.2. Automated Systems
  • 8.2.1. MicroScan Systems
  • 8.2.2. Phoenix Systems
  • 8.2.3. Vitek Systems
• 8.3. Disk Diffusion
• 8.4. Gradient Strip
• 8.5. Microdilution
• 8.6. Molecular Methods

9. Human Antimicrobial Susceptibility Testing Market, by Test Type

• 9.1. Introduction
• 9.2. Automated Testing
• 9.3. Manual Testing
  • 9.3.1. Agar Dilution
  • 9.3.2. Broth Microdilution
  • 9.3.3. Disk Diffusion
  • 9.3.4. Gradient Strip

10. Human Antimicrobial Susceptibility Testing Market, by Pathogen

• 10.1. Introduction
• 10.2. Fungi
• 10.3. Gram Negative Bacteria
  • 10.3.1. Enterobacteriaceae
  • 10.3.2. Non Enterobacteriaceae
• 10.4. Gram Positive Bacteria
• 10.5. Mycobacteria

11. Human Antimicrobial Susceptibility Testing Market, by Application

• 11.1. Introduction
• 11.2. Clinical Diagnostics
• 11.3. Pharmaceutical
• 11.4. Research

12. Human Antimicrobial Susceptibility Testing Market, by End User

• 12.1. Introduction
• 12.2. Clinics
• 12.3. Diagnostic Laboratories
• 12.4. Hospitals
• 12.5. Research Institutes

13. Human Antimicrobial Susceptibility Testing Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Human Antimicrobial Susceptibility Testing Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Human Antimicrobial Susceptibility Testing Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Accelerate Diagnostics Inc.
• 17.2. Alifax S.r.l.
• 17.3. Autobio Diagnostics Co., Ltd.
• 17.4. Becton, Dickinson and Company
• 17.5. Bio-Rad Laboratories, Inc.
• 17.6. BioMaxima S.A.
• 17.7. Bruker Corporation
• 17.8. Danaher Corporation
• 17.9. F. Hoffmann-La Roche AG
• 17.10. GeneFluidics, Inc.
• 17.11. HiMedia Laboratories Pvt. Ltd.
• 17.12. iFAST Diagnostics Ltd.
• 17.13. Liofilchem S.r.l.
• 17.14. Luminex Corporation
• 17.15. Microbiologics, Inc.
• 17.16. OpGen, Inc.
• 17.17. Prolab Incorporated
• 17.18. QIAGEN N.V.
• 17.19. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 17.20. Shimadzu Corporation
• 17.21. Siemens Healthineers AG
• 17.22. sifin diagnostics gmbh
• 17.23. T2 Biosystems, Inc.
• 17.24. Thermo Fisher Scientific Inc.
• 17.25. Titan Biotech Limited
• 17.26. Tulip Diagnostics (P) Ltd.
• 17.27. Zhuhai DL Biotech Co., Ltd.